iConnectHub

Login/Register

WeChat

For more information, follow us on WeChat

Connect

For more information, contact us on WeChat

Email

You can contact us info@ringiertrade.com

Phone

Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256

Top

Renal denervation market will pick up by 2016

Source:GlobalData Release Date:2013-10-25 145
Medical Equipment
Add to Favorites
Chronic heart failure to boost future growth with 25% share of renal denervation market by 2016, GlobalData forecasts

LONDON – Although the renal denervation market has previously been focused on the intervention’s treatment of patients with resistant and uncontrolled hypertension, it is expected that the next approved indication will be in chronic heart failure patients, says an analyst with research and consulting firm GlobalData.

According to Joseph Gregory, GlobalData analyst covering Surgical Devices, the uncontrolled hypertension population seemed to be the next likely target for treatment, but the condition will not receive an approved indication before heart failure. This is because the uncontrolled hypertension trials have been delayed in their initiation and their planned subject enrolment is significantly larger than the sole heart failure trial being conducted by Medtronic.

As mentioned in GlobalData’s previously published Expert Insight, the global renal denervation market is projected to experience lower-than-anticipated growth due to the magnitude of certain market barriers, such as reimbursement, the establishment of a new referral pattern, and the state of the clinical trial data. These barriers have dampened the global market’s current state so much, that it was only evaluated at $15.5m in 2012.

However, GlobalData forecasts that the treatment of chronic heart failure patients will reach a market share of 25% by 2016, adding an additional boost to the stagnant global denervation market.

GlobalData estimates that, following the trial, Medtronic will receive CE Mark approval for the condition by 2015.

“Most people only think of renal denervation as a treatment for people with hypertension. However, similar to patients with resistant hypertension, heart failure patients exhibit a significantly active sympathetic nervous system.

“Furthermore, the development of renal denervation in chronic heart failure is the first sign that the intervention is becoming more of a treatment for an overactive sympathetic nervous system, and less of a treatment explicitly for hypertension,” Mr Gregory said.Air Jordan XIV 14 Shoes
Add to Favorites
You May Like